<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04569071</url>
  </required_header>
  <id_info>
    <org_study_id>HK593202002</org_study_id>
    <nct_id>NCT04569071</nct_id>
  </id_info>
  <brief_title>Clinical Trial of MgLiTT for Medical Refractory Epilepsy</brief_title>
  <official_title>A Multi-center Clinical Trial to Evaluate the Efficacy and Safety of MRI-guided Laser Interstitial Thermal Therapy for Medical Refractory Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University International Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, prospective designed study to characterize the performance of&#xD;
      MRI-guided laser interstitial thermal therapy (MgLiTT) using the Sinovation Laser Ablation&#xD;
      System for the treatment of medical refractory epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Sinovation Laser Ablation System uses robot-assisted, precise, high-intensity laser light&#xD;
      to initiate necrosis of abnormal brain tissue through thermal ablation while limiting injury&#xD;
      to adjacent healthy tissue. MgLiTT has the advantages of precision, minimal invasive&#xD;
      procedure and real-time thermal monitoring.&#xD;
&#xD;
      Subjects who meet the study eligibility criteria and sign the informed consent form will&#xD;
      undergo the MgLiTT procedure. Subjects, or their caregivers, are required to keep a seizure&#xD;
      diary throughout the study, beginning after surgery. The study will monitor and record&#xD;
      subjects' seizure frequency, antiepileptic medications, and physical and emotional health.&#xD;
&#xD;
      Subjects treated with Sinovation Laser Ablation System will have at least 9 months of&#xD;
      follow-up. Throughout study participation, the study investigator will continuously monitor&#xD;
      and document both effectiveness and safety data at study appointments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2020</start_date>
  <completion_date type="Anticipated">February 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 8, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MgLiTT ablation rate</measure>
    <time_frame>Within 3 days after operation</time_frame>
    <description>Measurement of postsurgical MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure free rate</measure>
    <time_frame>90±7 days after operation</time_frame>
    <description>Follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure reduction rate</measure>
    <time_frame>90±7 days after operation</time_frame>
    <description>Follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>Within 1 day after operation</time_frame>
    <description>Medical recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postsurgical hospitalization</measure>
    <time_frame>Within 1 day after discharged from hospital</time_frame>
    <description>Medical recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination (MMSE) score</measure>
    <time_frame>Before and 90±7 days after operation</time_frame>
    <description>Range from 0 to 30; Lower score indicates worse cognitive impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in epilepsy-31 inventory (QOLIE-31) score</measure>
    <time_frame>Before and 90±7 days after operation</time_frame>
    <description>For adult; Range from 0 to 100; Higher score indicates better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in epilepsy for Adolescents (QOLIE-AD-48) score</measure>
    <time_frame>Before and 90±7 days after operation</time_frame>
    <description>For Adolescents; Range from 0 to 100; Higher score indicates better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs-body temperature</measure>
    <time_frame>Before and 2±1 days after operation</time_frame>
    <description>From medical recording; Centigrade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs-pulse</measure>
    <time_frame>Before and 2±1 days after operation</time_frame>
    <description>From medical recording; Times/minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs-respiratory rate</measure>
    <time_frame>Before and 2±1 days after operation</time_frame>
    <description>From medical recording; Times/minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs-blood pressure</measure>
    <time_frame>Before and 2±1 days after operation</time_frame>
    <description>From medical recording; Systolic pressure/diastolic pressure (mmHg)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Instrument performance evaluation</measure>
    <time_frame>Within 1 day after operation</time_frame>
    <description>Higher score indicates better instrument performance</description>
  </other_outcome>
  <other_outcome>
    <measure>The amount of bleeding</measure>
    <time_frame>During operation</time_frame>
    <description>Medical recording</description>
  </other_outcome>
  <other_outcome>
    <measure>Postsurgical complication rates</measure>
    <time_frame>Within 1 day after discharged from hospital</time_frame>
    <description>Medical recording</description>
  </other_outcome>
  <other_outcome>
    <measure>Failure free rate of laser ablation minimally invasive treatment kit</measure>
    <time_frame>Within 1 day after operation</time_frame>
    <description>Medical recording</description>
  </other_outcome>
  <other_outcome>
    <measure>Failure rate of magnetic resonance guided laser ablation system</measure>
    <time_frame>Within 1 day after operation</time_frame>
    <description>Medical recording</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>Within 1 day after discharged from hospital</time_frame>
    <description>Medical recording</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Sinovation Laser Ablation System treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sinovation Laser Ablation System treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sinovation Laser Ablation System</intervention_name>
    <description>In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.</description>
    <arm_group_label>Sinovation Laser Ablation System treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The age ranged from 6 months to 70 years old;&#xD;
&#xD;
          -  Previous diagnosis of drug-resistant epilepsy with focal lesions;&#xD;
&#xD;
          -  The average seizure frequency was more than 2 times/month within 3 months;&#xD;
&#xD;
          -  Surgical treatment is suitable for epilepsy;&#xD;
&#xD;
          -  The subjects or their guardians can understand the purpose of the trial, show adequate&#xD;
             compliance with the trial protocol, and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MRI contraindication;&#xD;
&#xD;
          -  Patients with severe coagulation dysfunction;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Subjects who have participated in clinical trials of any other drugs or medical&#xD;
             devices within 3 months;&#xD;
&#xD;
          -  Evidence of severe or uncontrollable systemic diseases, as judged by the researchers;&#xD;
&#xD;
          -  Subjects considered unsuitable for the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Zhang, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kai Zhang, Dr.</last_name>
    <phone>+86 13501196619</phone>
    <email>zhangkai62035@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiu Wang, Dr.</last_name>
    <phone>+86 13520908011</phone>
    <email>wang19001@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Zhang</last_name>
      <phone>+86 13501196619</phone>
      <email>zhangkai62035@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic surgery</keyword>
  <keyword>Thermal ablation</keyword>
  <keyword>Medical refractory epilepsy</keyword>
  <keyword>Epilepsy surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We may only share clinical information (rather privacy information) in academic or other reasonable request.</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After the clinical trials.</ipd_time_frame>
    <ipd_access_criteria>reasonable requests.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

